Powered by

NeuroBo to start trial of NB-01 for diabetic neuropathic pain

Jan 09, 2019 - Marketline Newswire

NeuroBo Pharmaceuticals is set to begin a Phase III trial to analyse the efficacy of NB-01 for the treatment of diabetic neuropathic pain in the second quarter of this year.

The double-blind, placebo controlled, 12-week study is expected to randomise nearly 717 adults patients at up to 80 sites in the US.NeuroBo also intends to start a second global pivotal Phase III study of NB-01 with a similar design in mid-2020.The primary goal of both trials is a change from baseline to week 12 as mea...